Literature DB >> 7706296

Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes.

H Toyoda1, T Komurasaki, D Uchida, Y Takayama, T Isobe, T Okuyama, K Hanada.   

Abstract

Epiregulin, a novel epidermal growth factor (EGF)-related growth regulating peptide, was purified from conditioned medium of the mouse fibroblast-derived tumor cell line NIH3T3/clone T7. It was a 46-amino-acid single chain polypeptide, and its amino acid sequence exhibited 24-50% amino acid sequence identity with sequences of other EGF-related growth factors. Epiregulin exhibited bifunctional regulatory properties: it inhibited the growth of several epithelial tumor cells and stimulated the growth of fibroblasts and various other types of cells. Epiregulin bound to the EGF receptors of epidermoid carcinoma A431 cells much more weakly than did EGF, but was nevertheless much more potent than EGF as a mitogen for rat primary hepatocytes and Balb/c 3T3 A31 fibroblasts. These findings suggest that epiregulin plays important roles in regulating the growth of epithelial cells and fibroblasts by binding to receptors for EGF-related ligands.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706296     DOI: 10.1074/jbc.270.13.7495

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  70 in total

Review 1.  ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.

Authors:  R Pinkas-Kramarski; I Alroy; Y Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

2.  Receptor-based antidote for diphtheria.

Authors:  Jeong-Heon Cha; Joanna S Brooke; Mee Young Chang; Leon Eidels
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

3.  Expression in mammalian cell cultures reveals interdependent, but distinct, functions for Star and Rhomboid proteins in the processing of the Drosophila transforming-growth-factor-alpha homologue Spitz.

Authors:  John C Pascall; Jane E Luck; Kenneth D Brown
Journal:  Biochem J       Date:  2002-04-15       Impact factor: 3.857

4.  Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation.

Authors:  K Elenius; S Paul; G Allison; J Sun; M Klagsbrun
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

5.  Phenotypic variation resulting from a deficiency of epidermal growth factor receptor in mice is caused by extensive genetic heterogeneity that can be genetically and molecularly partitioned.

Authors:  Karen E Strunk; Vicky Amann; David W Threadgill
Journal:  Genetics       Date:  2004-08       Impact factor: 4.562

6.  Neuregulins rescue PC12-ErbB-4 cells from cell death induced by beta-amyloid peptide: involvement of PI3K and PKC.

Authors:  Ayelet Di Segni; Ezra Shaharabani; Reuven Stein; Ronit Pinkas-Kramarski
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

7.  Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network.

Authors:  E Tzahar; J D Moyer; H Waterman; E G Barbacci; J Bao; G Levkowitz; M Shelly; S Strano; R Pinkas-Kramarski; J H Pierce; G C Andrews; Y Yarden
Journal:  EMBO J       Date:  1998-10-15       Impact factor: 11.598

8.  Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin.

Authors:  D S Taylor; X Cheng; J E Pawlowski; A R Wallace; P Ferrer; C J Molloy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop.

Authors:  Nicole E Willmarth; Andrea Baillo; Michele L Dziubinski; Kristy Wilson; David J Riese; Stephen P Ethier
Journal:  Cell Signal       Date:  2008-10-14       Impact factor: 4.315

10.  Amino-terminal deletion of heparin-binding epidermal growth factor-like growth factor4-127 stimulates cell proliferation but lacks insulin-like activity.

Authors:  Z Zhou; P A Harding
Journal:  Cell Prolif       Date:  2007-04       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.